Drug regimens used as the initial maintenance therapy of symptomatic heart failure related to dilated cardiomyopathy
| Drug combinations | n/total | % |
| Single-drug regimen | ||
| ACE-I | 5/100 | 5 |
| Two-drug regimen | ||
| ACE-I+Loop diuretic | 12/100 | 12 |
| ACE-I+Aldosterone antagonist | 1/100 | 1 |
| ACE-I+Beta-blocker | 4/100 | 4 |
| ACE-I+Thiazide diuretic | 1/100 | 1 |
| Aldosterone antagonist+Loop diuretic | 2/100 | 2 |
| Three-drug regimen | ||
| ACE-I+Aldosterone antagonist+Loop diuretic | 20/100 | 20 |
| ACE-I+Aldosterone antagonist+Beta-blocker | 4/100 | 4 |
| ACE-I+Aldosterone antagonist+Thiazide diuretic | 1/100 | 1 |
| ACE-I+Aldosterone antagonist+Cardiac glycoside | 3/100 | 3 |
| ACE-I+Beta blocker+Loop diuretic | 7/100 | 7 |
| ACE-I+Beta blocker+Thiazide diuretic | 1/100 | 1 |
| ACE-I+Cardiac glycoside+Loop diuretic | 4/100 | 4 |
| Aldosterone antagonist+Loop diuretic+Thiazide | 1/100 | 1 |
| Four-drug regimen | ||
| ACE-I+Aldosterone antagonist+Beta blocker+Loop diuretic | 14/100 | 14 |
| ACE-I+Aldosterone antagonist+Beta blocker+Thiazide diuretic | 4/100 | 4 |
| ACE-I+Aldosterone antagonist+Loop diuretic+Cardiac glycoside | 3/100 | 3 |
| ACE-I+Aldosterone antagonist+Loop diuretic+Thiazide diuretic | 1/100 | 1 |
| ACE-I+ARB + Loop diuretic+Cardiac glycoside | 1/100 | 1 |
| Aldosterone antagonist+Beta blocker+Cardiac glycoside+Loop diuretic | 1/100 | 1 |
| Five-drug regimen | ||
| ACE-I+Aldosterone antagonist+Beta blocker+Loop diuretic+Thiazide diuretic | 4/100 | 4 |
| ACE-I+Aldosterone antagonist+Beta blocker+Cardiac glycoside+Loop diuretic | 3/100 | 3 |
| ACE-I+Aldosterone antagonist+Cardiac glycoside+Loop diuretic+Acetylsalicylic acid | 1/100 | 1 |
| ACE-I+Aldosterone antagonist+Beta blocker+Loop diuretic+Ivabradine | 1/100 | 1 |
| Six-drug regimen | ||
| ACE-I+Aldosterone antagonist+ARB + Beta-blocker+Loop diuretic+Thiazide diuretic | 1/100 | 1 |
Most of the participants start with 2 (20%), 3 (41%) or 4 (24%) drugs in combination. One third of participants (34%) reported starting with a drug combination that includes four or more drugs. Figures for the three drug regimens that were reported most frequently have been emphasised in bold.
ACE-I, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blockers.